The Maltese Release Company
The Maltese Release Company (TMRC) is a recently established, privately owned company, located in Malta. TMRC provides access to testing and release services in any dosage form and offers you analytical method development and validation.
The Maltese Release Company (TMRC) is a recently established, privately owned company, located in Malta in the pharmaceutical industrial park of Hal Far.
TMRC was born from a Joint Venture between COMBINO PHARM and ALFRED E. TIEFENBACHER, to offer a vast range of services to pharmaceutical companies.
The strategic location of TMRC permits us to perform EU-GMP testing and release of pharmaceutical products even before the end of patent term, allowing our clients the great opportunity to start selling products in the EU market from day one, a huge advantage when compared to other competitors.
The company counts on a diverse team of highly skilled and experienced individuals both in quality control analysis as well as quality assurance.
For more information please contact us info@themalteserelease.com.mt or visit www.themalteserelease.com.mt
Drug Solutions Podcast: Novel Drug Delivery Approaches: Refining AAV Vector Deliveries
May 30th 2025In this podcast episode, we discuss novel approaches to drug delivery, specifically regarding adeno-associated virus (AAV) vectors, as viewed by two industry experts who recently exhibited at the annual ASGCT meeting.
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Prokaryotics Licenses Gram-Negative Antibiotic Potentiator from Northern Antibiotics
June 26th 2025Prokaryotics will gain worldwide rights to develop, manufacture, and commercialize NAB741, a non-bioactive polymyxin designed to increase permeability of the outer membrane of Gram-negative bacteria.
